Bowman Cox
Executive Editor
Latest From Bowman Cox
BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days
Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.
As Emergent Partnership Dissolves, BARDA Looks To Revamp Post-COVID Pandemic Preparedness
BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.
How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention
Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.
How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention
Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.
Fewer Observations, Shift In Emphasis Seen In FDA's Pandemic-Reduced Inspections
US agency mostly saw less of the same when it scaled back inspectional activity during COVID-19, but observed more training and equipment issues.
BARDA Expands US Domestic Production Of Single-Use Systems For Vaccine Manufacturing
FlexBiosys wins award; others to follow. New capacity may also benefit manufacture of monoclonal antibodies and cell and gene therapies.